Review
Schistosomiasis vaccine discovery using immunomics
-
* Corresponding author: Patrick Driguez patrick.driguez@qimr.edu.au
1 Molecular Parasitology Laboratory, The Queensland Institute of Medical Institute, Herston, Queensland 4006, Australia
2 School of Population Health, University of Queensland, Herston, Queensland 4006, Australia
3 Molecular Vaccinology Laboratory, The Queensland Institute of Medical Institute, Herston, Queensland 4006, Australia
4 Helminth Biology Laboratory, The Queensland Institute of Medical Institute, Herston, Queensland 4006, Australia
5 Department of Medicine, University of California, Irvine, CA 92067, USA
Parasites & Vectors 2010, 3:4 doi:10.1186/1756-3305-3-4
Published: 28 January 2010Abstract
The recent publication of the Schistosoma japonicum and S. mansoni genomes has expanded greatly the opportunities for post-genomic schistosomiasis vaccine research. Immunomics protein microarrays provide an excellent application of this new schistosome sequence information, having been utilised successfully for vaccine antigen discovery with a range of bacterial and viral pathogens, and malaria.
Accordingly, we have designed and manufactured a Schistosoma immunomics protein microarray as a vaccine discovery tool. The microarray protein selection combined previously published data and in silico screening of available sequences for potential immunogens based on protein location, homology to known protective antigens, and high specificity to schistosome species. Following cloning, selected sequences were expressed cell-free and contact-printed onto nitrocellulose microarrays. The reactivity of microarray proteins with antisera from schistosomiasis-exposed/resistant animals or human patients can be measured with labelled secondary antibodies and a laser microarray scanner; highly reactive proteins can be further assessed as putative vaccines. This highly innovative technology has the potential to transform vaccine research for schistosomiasis and other parasitic diseases of humans and animals.